# 3.3.3 Summary of Safety Results

**Page range:** 58–59

```text
3.3.3
Summary of Safety Results
A search of the Company Safety Database for pralsetinib identified a total of 806 cases
reporting 923 AEs of interest based on the MedDRA SOC, Infections and Infestations.
Of these 806 cases, 740 cases were serious and 66 were non-serious. As per the case
analysis strategy described in Section 2.3.1 , the 740 serious cases reporting 794
serious AEs of infection were further analyzed. Out of these 794 serious events, 86 were

59
Drug Safety Report No: 1132062
Grade 5, 47 were Grade 4, 311 were Grade 3, 66 were Grade 2 and 12 were Grade 1
infections. For the remaining 272 AEs of infection (reported from 249 cases), severity
grades were not reported. The key features of the 387 cases reporting ≥Grade 3 AEs of
infection (444/794) are summarized below:

Out of the 387 cases, where reported, 199 were males and 181 were females.

The most frequently reported PT was Pneumonia (117/444) followed by Sepsis
(45/444), Urinary tract infection (38/444), COVID 19 (30/444), COVID 19 pneumonia
(16/444) and Pneumocystis jirovecii pneumonia (8/444).

A total of 86 events resulted in a fatal outcome and the PTs reported were
Pneumonia (n=25), Sepsis (n=19), COVID 19 (n=18), Septic shock (n=6), COVID-
```